• 1. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 2. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 3. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

4-Fluoro-1H-indol-7-ol (CAS No. 1167056-43-0): An Overview of a Promising Compound in Pharmaceutical Research

4-Fluoro-1H-indol-7-ol (CAS No. 1167056-43-0) is a compound that has garnered significant attention in the field of pharmaceutical research due to its unique chemical structure and potential therapeutic applications. This compound belongs to the indole family, a class of heterocyclic aromatic compounds that are widely studied for their diverse biological activities. The presence of a fluorine atom at the 4-position and a hydroxyl group at the 7-position imparts distinct properties to this molecule, making it an intriguing candidate for various medicinal chemistry applications.

The chemical structure of 4-fluoro-1H-indol-7-ol can be represented as C₉H₇FO₂. The indole core is a fundamental scaffold in many bioactive molecules, and the introduction of a fluorine atom and a hydroxyl group significantly alters its physicochemical properties. Fluorine substitution is known to enhance the metabolic stability and lipophilicity of molecules, while the hydroxyl group can participate in hydrogen bonding, thereby influencing the compound's binding affinity to biological targets.

In recent years, 4-fluoro-1H-indol-7-ol has been extensively studied for its potential as a lead compound in drug discovery. One of the key areas of interest is its role as an inhibitor of specific enzymes involved in various disease pathways. For instance, research has shown that this compound exhibits potent inhibitory activity against certain kinases, which are crucial enzymes in signal transduction pathways associated with cancer and inflammatory diseases. This makes 4-fluoro-1H-indol-7-ol a promising candidate for the development of targeted therapies.

Beyond its enzymatic inhibition properties, 4-fluoro-1H-indol-7-ol has also been investigated for its potential neuroprotective effects. Studies have demonstrated that this compound can modulate the activity of neurotransmitter receptors and ion channels, which are implicated in neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. The ability to influence these pathways suggests that 4-fluoro-1H-indol-7-ol could be developed into novel treatments for these debilitating conditions.

The pharmacokinetic profile of 4-fluoro-1H-indol-7-ol is another critical aspect that has been explored in preclinical studies. Research indicates that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties, which are essential for its effective delivery to target tissues. Additionally, the compound has shown low toxicity in animal models, further supporting its potential as a safe and effective therapeutic agent.

In the context of drug development, the structural modifications of 4-fluoro-1H-indol-7-ol have been a focal point for medicinal chemists. By introducing various functional groups or altering the substitution pattern on the indole ring, researchers aim to optimize the compound's pharmacological properties. For example, derivatives with enhanced potency or improved selectivity have been synthesized and evaluated in vitro and in vivo models.

The clinical potential of 4-fluoro-1H-indol-7-ol is supported by several preclinical studies that have demonstrated its efficacy in relevant disease models. For instance, in cancer research, this compound has shown significant antiproliferative effects against various tumor cell lines. In neurodegenerative disease models, it has exhibited neuroprotective effects by reducing oxidative stress and preventing neuronal cell death.

In conclusion, 4-fluoro-1H-indol-7-ol (CAS No. 1167056-43-0) is a promising compound with a wide range of potential applications in pharmaceutical research. Its unique chemical structure and favorable biological properties make it an attractive lead for drug discovery efforts targeting various diseases. Ongoing research continues to uncover new insights into its mechanisms of action and therapeutic potential, positioning it as a valuable asset in the development of innovative treatments.

• 606131-17-3(Benzenesulfonamide, 4-[(5,6-dimethyl-1H-benzimidazol-1-yl)sulfonyl]-N-ethyl-N-(phenylmethyl)- (9CI))
• 606131-18-4(1H-Benzimidazole,5,6-dimethyl-1-[[4-[(2-methyl-1-piperidinyl)sulfonyl]phenyl]sulfonyl]-(9CI))
• 606131-23-1(1H-Benzimidazole,5,6-dimethyl-1-[[4-(1-piperidinylsulfonyl)phenyl]sulfonyl]-(9CI))
• 320740-72-5(5,6-dimethyl-1-[(4-methylphenyl)sulfonyl]-1H-benzimidazole)
• 606131-22-0(Benzenesulfonamide, 4-[(5,6-dimethyl-1H-benzimidazol-1-yl)sulfonyl]- (9CI))
• 606131-19-5(1H-Benzimidazole,5,6-dimethyl-1-[[4-(1-pyrrolidinylsulfonyl)phenyl]sulfonyl]-(9CI))
• 606131-21-9(Benzenesulfonamide, 4-[(5,6-dimethyl-1H-benzimidazol-1-yl)sulfonyl]-N,N-dimethyl- (9CI))
• 606131-20-8(1H-Benzimidazole,1-[[4-[(2-ethyl-1-piperidinyl)sulfonyl]phenyl]sulfonyl]-5,6-dimethyl-(9CI))
• 325810-41-1(5,6-dimethyl-1-(phenylsulfonyl)-1H-benzimidazole)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)